The stock of Tenax Therapeutics, Inc. (NASDAQ: TENX) closed the previous session at $2.08, meaning its value has risen 307.76% higher than its 52-week low. In intraday trading, Tenax stock hit a low of $2.03 and a high of $2.47.
A recent trading session has witnessed an intraday change of just 16.85% while TENX stock has had a 52-week high of $3.68 and a low of $0.51. An increase in TENX stock accompanied the positive results of a phase 2 study on its candidate for the treatment of cardiovascular disease.
The TENX study found what?
A specialty pharmaceutical company, Tenax Therapeutics, focuses on identifying and developing products with high unmet medical needs for cardiovascular diseases and pulmonary diseases. TENX facilitates access to world-class scientific advisory teams, which include globally recognized experts in pulmonary hypertension.
On Friday, Tenax announced that it had published positive results from its Phase 2 HELP study that examined levosimendan’s efficacy in patients with Cardiopulmonary Hypertension associated with Heart Failure.
- TENX has published a new publication titled Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial.
- This article was published in the Journal of the American College of Cardiology.
- Through this 6-week study, TENX examined the haemodynamics of individuals who were invasively monitored by their cardiovascular system as well as secondary clinical outcomes such as a 6-minute walk test.
- According to the TENX study published in the journal, 84% of the participants responded.
- The primary endpoint of exercise-PCWP was not significantly reduced by levosimendan, compared with placebo, but PCWP was effectively reduced across all phases of exercise.
- Compared to a control group, 6 MWD experienced a 29.5 meter improvement from the levosimendan treatment.
TENX’s further plans:
Levosimendan is currently in Phase 2 clinical trials to treat PH-HFpEF and developed by Tenax (TENX), which also has the rights to develop and commercialize this drug. Based on the TENX study’s results, further study of levosimendan in PH-HFpEF patients is warranted since this is the first drug that could demonstrate improved cardiomyopathy and improved six-minute walking distance compared to placebo.